EYE is getting a bit of press coverage today regarding yesterday’s announcement about the commencement of a clinical trial (see their LinkedIn account). If the buying comes in it wouldn’t take much for this stock to rally hard since there’s such a low SOI + high insider and institutional ownership. Seems ready for a bolly squeeze as well - super tight trading. OBV looks nice too.
